Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors

NCT: NCT07019259 · RECRUITING

NCT IDNCT07019259
StatusRECRUITING
Start Date2025-06-30
Completion2027-04
SponsorYale University (OTHER)
First posted
Last updated

Brief Summary

The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.

Frequently Asked Questions

What is Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors?

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors is a clinical trial registered under NCT07019259. Current status: RECRUITING.

What is the status of NCT07019259?

The current status of NCT07019259 (Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors) is: RECRUITING.

When did Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors start?

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors started on 2025-06-30.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.